January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

Introduction of biosimilars for the rheumatology drug adalimumab ... could dissuade most prescribers from switching. Another example (and perhaps driver) of that latter success came in June ...

P.C., a seven-office rheumatology practice in Maryland; Washington, DC; and Virginia. Many other biosimilars for rheumatologic medications are launching in the next 2 years, “and we’re very ...

according to data published in Clinical Rheumatology. The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

For example, the price of Humira biosimilars in Denmark decreased by 82% from September 2018 to December 2018. By 2019, the average market share across Europe of Humira-referenced biosimilars was ...

In the U.S., rebates can play a role in perpetuating the suboptimal market for biosimilars. In January, for example, Amjevita (adalimumab-atto) became the first Humira-referenced biosimilar to ...

for example, an animal cell or microorganism. The first biological medicine to be approved for use in the European Union for a particular condition is called the biological reference medicine. A ...